Education
About Us
Working with TipRanks
Follow Us
Oncolytics Biotech (ONCY)
NASDAQ:ONCY
ONCY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.58 - $1.53
Previous CloseN/A
Volume216.96K
Average Volume (3M)278.04K
Market Cap
$55.09M
Enterprise Value$88.49M
Total Cash (Recent Filing)C$15.94M
Total Debt (Recent Filing)C$1.06M
Price to Earnings (P/E)―
Beta0.44
Next Earnings
May 02, 2025EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding86,421,590
10 Day Avg. Volume216,205
30 Day Avg. Volume278,042
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$3.75Price Target Upside504.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Oncolytics Biotech News
PremiumCompany Announcements
Oncolytics Biotech Advances Cancer Trials with Promising Results
PremiumCompany Announcements
Oncolytics Biotech’s Earnings Call: Clinical Progress Amid Challenges---
Bulls Say, Bears Say
Bulls Say
Clinical Development ProgressOncolytics continues to execute well on its late-stage clinical development plan for pelareorep in metastatic breast cancer and metastatic pancreatic ductal adenocarcinoma, which should lead to near-term value realization for shareholders.
Clinical Trial SuccessPelareorep and paclitaxel showed a significant improvement in overall survival rates compared to paclitaxel alone, highlighting the potential effectiveness of the combination therapy.
Regulatory ProgressRegulatory alignment with the FDA on trial design and compelling survival data support confidence in the potential registration-enabling program in breast cancer, which may attract robust partnership opportunities.
Bears Say
Capital Raising ConcernsOncolytics Biotech is expected to need to raise capital soon to fund its programs, which may lead to potential dilution and has resulted in the lowering of the 12-month price target.
Financial StabilityThe estimated cash burn and current cash reserves indicate a potential need for additional funding, which could impact financial stability.
---
Ownership Overview
0.68% Insiders
0.05% Mutual Funds
0.87% Other Institutional Investors
98.40% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ONCY FAQ
What was Oncolytics Biotech’s price range in the past 12 months?
Oncolytics Biotech lowest stock price was $0.58 and its highest was $1.53 in the past 12 months.
What is Oncolytics Biotech’s market cap?
Oncolytics Biotech’s market cap is $55.09M.
When is Oncolytics Biotech’s upcoming earnings report date?
Oncolytics Biotech’s upcoming earnings report date is May 02, 2025 which is in 35 days.
How were Oncolytics Biotech’s earnings last quarter?
Oncolytics Biotech released its earnings results on Mar 07, 2025. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.085 by $0.015.
Is Oncolytics Biotech overvalued?
According to Wall Street analysts Oncolytics Biotech’s price is currently Undervalued.
Does Oncolytics Biotech pay dividends?
Oncolytics Biotech does not currently pay dividends.
What is Oncolytics Biotech’s EPS estimate?
Oncolytics Biotech’s EPS estimate is -0.07.
How many shares outstanding does Oncolytics Biotech have?
Oncolytics Biotech has 86,421,590 shares outstanding.
What happened to Oncolytics Biotech’s price movement after its last earnings report?
Oncolytics Biotech reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.085. Following the earnings report the stock price went down -6.757%.
Which hedge fund is a major shareholder of Oncolytics Biotech?
Currently, no hedge funds are holding shares in ONCY
---
Oncolytics Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.75 (504.84% Upside)
$3.75 (504.84% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 10.7%
Last 30 Days ▼ 10.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.44%
12-Months-Change
Fundamentals
Return on Equity
-184.69%
Trailing 12-Months
Asset Growth
-52.32%
Trailing 12-Months
Company Description
Oncolytics Biotech
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
---
ONCY Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted significant clinical advancements and promising business development efforts, particularly in breast and gastrointestinal cancers. However, financial challenges, leadership transitions, and regulatory uncertainties pose notable concerns.Read More>---
ONCY Stock 12 Month Forecast
Average Price Target
$3.75
▲(504.84% Upside)
Technical Analysis
Best Analysts Covering ONCY
1 Year
1 Year Success Rate
5/15 ratings generated profit
1 Year Average Return
-17.67%
reiterated a buy rating 5 months ago
Copying John Newman's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -17.67% per trade.
---